Navigation Links
OncoGenex Reports Second Quarter 2009 Financial Results
Date:8/6/2009

stigation. - The Company reached an agreement with the U.S. Food and Drug Administration (FDA) via the special protocol assessment process (SPA) on an amendment to the design of a phase 3 registration trial of OGX-011. The FDA has agreed on modifications to the study population of a previously reviewed phase 3 trial featuring survival as the primary endpoint. The study population has been modified to evaluate patients receiving first-line chemotherapy, rather than those receiving second-line chemotherapy. The FDA has agreed that the amended protocol adequately addresses the objectives necessary to support a regulatory submission. - In June 2009 the Company was added to the Russell 3000(R) Index, the Russell 2000(R) Index and the Russell Microcap(R) Index as part of the annual reconstitution of Russell indexes.

Conference Call Today at 4:30 p.m. ET

OncoGenex management will host a conference call at 4:30 p.m. Eastern Time today to provide a business update and discuss the first quarter results. A live webcast will be available through the Events and Presentations Web page found in the Investor Relations section of the OncoGenex Web site at www.ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-548-7912 (U.S. Canada) or 719-325-4897 (International). A webcast replay will be available approximately two hours after the call and will be archived at the same Web location for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique op
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 17, 2014 This report ... Quartz Tubing industry. For an overview analysis, the ... application, industry chain structure, industry overview, policy analysis, ... tubing industry has witnessed rapid development with ... of acquisitions. This report mentions quartz tubing upstream ...
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 ... today that it has entered into a technology ... Company (ADM) to apply DNA2.0’s proprietary protein engineering ... engineering process. , “We are extremely excited that ... engineering platform. This proprietary bioengineering technology has ...
(Date:12/17/2014)... AUSTIN, Texas , Dec. 16, 2014  Vermillion, ... company focused on gynecologic disease, today announced the next ... into a premier bio-analytics solutions provider with the naming ... to President and Chief Executive Officer, while current Chairman ... will continue to serve as Chairman. These changes are ...
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... SEATTLE, Jan. 11 Cell Therapeutics, Inc.,(CTI) (Nasdaq ... per le Societa e la Borsa ("CONSOB") granted ... the procedures set,forth by Article 8 and Article ... offerings of CTI,s common stock representing more than ...
... FDA Warns Pharmacies Not to Compound Commonly-Prescribed Hormone Estriol, ... Not to Use the ... statement regarding,compounded estrogens -- which include estradiol and estriol --,progesterone, ... medical experts in the field of Women,s Hormones," remarks Cheryle,Hart, ...
... CITY, Calif., Jan. 11 Maxygen, Inc.,(Nasdaq: ... development of,improved protein drugs, today announced that it ... Healthcare Conference on Thursday,January 17, 2008 at 7:45 ... will present. A live webcast of the presentation ...
Cached Biology Technology:Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus 2Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus 3Bio-Identical Hormone Menopause Doctor Responds to Outrageous FDA News 2
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
(Date:11/21/2014)... 18, 2014 According to a ... Systems (Video, RFID, Access Control, Intrusion Detection, Parking Management, ... Government), Component Service Geography - Global Forecasts to 2020", ... projected to be around $25 Billion in 2014 and ... at a CAGR of 8.69%. Browse 116 ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... Researchers report that performing angioplasty (a treatment that involves ... a clogged artery to help widen it) on veins ... an effective way to treat the venous abnormalities found ... The findings were presented at the Society of Interventional ...
... the ocean,s fisheries, solutions can be found in a surprising ... on March 23 in the journal Fish and Fisheries ... seven centuries of human habitation in Hawaii and the Florida ... and evaluated the management strategies associated with periods of sustainability. ...
... and Lawrence Berkeley National Lab have discovered a new route ... electron) can move from one molecule to another a ... is a radically new way by which proton transfer may ... Dornsife College of Letters, Arts and Sciences. Krylov is a ...
Cached Biology News:Interventional radiology: Mitigating symptoms, improving quality of life of MS patients 2Interventional radiology: Mitigating symptoms, improving quality of life of MS patients 3Ancient civilizations reveal ways to manage fisheries for sustainability 2Ancient civilizations reveal ways to manage fisheries for sustainability 3Scientists discover new method of proton transfer 2
... yellow solution. In PBS ... and other proprietary stabilizers; ... formulated to stabilize activity ... conjugates at high conjugate ...
... WinMelt software is used ... of any DNA sequence up ... in optimizing placement of primers ... detection by denaturing gradient gel ...
... GT cell and PowerPac basic power supply are ... acids in agarose gels. The Mini-Sub cell GT ... and electrodes, a 7 x 7 cm UV-transparent ... and two 1.5 mm fixed-height combs (8- and ...
... and PowerPac basic power supply are used for ... agarose gels. The mini format cell includes a ... leveling bubble. The PowerPac basic power supply, 100-120 ... 4-400 mA, and 75 W. Power cord and ...
Biology Products: